Get Premium to unlock powerful stock data
Evelo Biosciences Inc logo

Evelo Biosciences Inc

$ 1.46 -0.25 (-14.62%) 09:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 78.34M
Enterprise V:
$ 107.95M
Volume:
203.48K
Avg Vol (2M):
312.88K
Volume:
203.48K
Market Cap $:
78.34M
PE Ratio:
At Loss
Avg Vol (2-Month):
312.88K
Enterprise Value $:
107.95M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Evelo Biosciences Inc
NAICS : 325411 SIC : 2833
620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139
Description
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Name Current Vs Industry Vs History
Cash-To-Debt 0.71
Equity-to-Asset -0.29
Debt-to-Equity -3.32
Debt-to-EBITDA -0.48
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 19.62
9-Day RSI 26.04
14-Day RSI 30.17
6-1 Month Momentum % -72.68
12-1 Month Momentum % -80.34

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.67
Quick Ratio 2.67
Cash Ratio 2.45

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19
Name Current Vs Industry Vs History
ROE % -354.09
ROA % -110.33
ROIC % -562.54
ROC (Joel Greenblatt) % -727.58
ROCE % -127.59

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -0.87
EV-to-EBITDA -0.89
EV-to-FCF -1.07
Earnings Yield (Greenblatt) % -114.78

Financials (Next Earnings Date:2022-07-29 Est.)

EVLO's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:EVLO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -2.32
Beta 2.36
Volatility % 79.51
14-Day RSI 30.17
14-Day ATR ($) 0.28385
20-Day SMA ($) 2.13325
12-1 Month Momentum % -80.34
52-Week Range ($) 1.45 - 17.125
Shares Outstanding (Mil) 53.66

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Evelo Biosciences Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More